Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biotricity, Inc. - Common Stock (NQ: BTCY )

0.4631 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biotricity, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
Biotricity Provides Updated Guidance for Earlier than Expected Path to Profitability due to Growing Revenues and Improving Margins
Via ACCESSWIRE
Biotricity Announces Inclusion as a Supplier to A Prominent Medical System That Services 21 States
Via ACCESSWIRE
Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals
Via ACCESSWIRE
Biotricity Reports Continued Margin Improvement and Reduced Losses in its First Quarter Fiscal Year 2025
Via ACCESSWIRE
BTCY Stock Earnings: Biotricity Reported Results for Q1 2025
Biotricity just reported results for the first quarter of 2025. 
Via InvestorPlace
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Via ACCESSWIRE
Biotricity Provides Year-End Guidance with Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
Via ACCESSWIRE
LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
Via ACCESSWIRE
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Biotricity Announces Accelerated Path to EBITDA Positive
Via ACCESSWIRE
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program
Via ACCESSWIRE
BTCY Stock Earnings: Biotricity Beats EPS, Misses Revenue for Q4 2024
BTCY stock results show that Biotricity beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability
Via ACCESSWIRE
Biotricity to Host Fourth Quarter and Fiscal Year 2024 Financial Results and Business Update Call on June 27
Via ACCESSWIRE
Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
Via ACCESSWIRE
Biotricity Preferred Shareholders Show Increased Commitment and Support of the Company by Converting Almost All Preferred A Shares into Restricted Common Stock
Via ACCESSWIRE
Biotricity Announces the Upcoming Launch of the First-Ever Direct-to-Patient Cardiac Screening Service, Targeting the $1.05B Home Heart Health Market
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies
Via ACCESSWIRE
Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers
Via ACCESSWIRE
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
Via ACCESSWIRE
Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network
Via ACCESSWIRE
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
Via ACCESSWIRE
LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.